---
id: acr-rheumatoid-arthritis-2021
title: "2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis"
short_title: "ACR Rheumatoid Arthritis 2021"

organization: American College of Rheumatology
collaborators: null
country: US
url: https://rheumatology.org/rheumatoid-arthritis-guideline
doi: 10.1002/acr.24596
pmid: 34101387
open_access: true

specialty: rheumatology
guideline_type: clinical-practice
evidence_system: GRADE
conditions:
  - rheumatoid arthritis
  - inflammatory arthritis
tags:
  - DMARDs
  - methotrexate
  - biologics
  - TNF inhibitors
  - JAK inhibitors
  - treat-to-target

publication_date: 2021-06-08
previous_version_date: 2015-11-06
status: current
supersedes: acr-rheumatoid-arthritis-2015
superseded_by: null

pdf_path: null
has_pdf: false
last_reviewed: 2025-12-21
---

## Scope

Evidence-based recommendations for pharmacologic treatment of rheumatoid arthritis including DMARDs, biologics, and targeted synthetic DMARDs, with emphasis on treat-to-target approach.

## Notes

Companion guideline on exercise, rehabilitation, diet, and integrative interventions published in 2022 (ACR 2022 Integrative Interventions). Current most recent pharmacologic treatment guideline.
